Aiolos: going for best in class with a long-acting TSLP mAb for asthma

With a long-acting mAb that may enable a twice-yearly dosing schedule, Aiolos believes it has a shot at a best-in-class asthma treatment. The company launched on Tuesday with a $245 million series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments.

Co-founder and CEO Khurem Farooq told BioCentury that he and co-founder and board member Tony Adamis, who knew each other well from their time at Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), decided to create a company around an in-licensed immunology product...